389 research outputs found
Homozygous mutation in the prokineticin-receptor2 gene (Val274Asp) presenting as reversible Kallmann syndrome and persistent oligozoospermia: case report.
Prokineticin 2 (Prok2) or prokineticin-receptor2 (Prok-R2) gene mutations are associated with Kallmann syndrome
(KS). We describe a new homozygous mutation of Prok-R2 gene in a man displaying KS with an apparent reversal of
hypogonadism. The proband, offspring of consanguineous parents, presented at age 19 years with absent puberty, no
sense of smell, low testosterone and gonadotrophin levels. Magnetic resonance imaging showed olfactory bulb absence.
The patient achieved virilization and spermatogenesis with gonadotrophin administration. Two years after discontinuing
hormonal therapy, he maintained moderate oligozoospermia and normal testosterone levels. Prok2 and Prok-
R2 gene sequence analyses were performed. The proband had a homozygous mutation in Prok-R2 exon 2 that harbours
the c.T820>A base substitution, causing the introduction of an aspartic acid in place of valine at position 274
(Val274Asp). His mother had the same mutation in heterozygous state. This report describes a novel homozygous
mutation of Prok-R2 gene in a man with variant KS, underlying the role of Prok-R2 gene in the olfactory and reproductive
system development in humans. Present findings indicate that markedly delayed activation of gonadotrophin
secretion may occur in some KS cases with definite gene defects, and that oligozoospermia might result from a variant
form of reversible hypogonadotrophic hypogonadism
Involvement of hypothalamus autoimmunity in patients with autoimmune hypopituitarism: role of antibodies to hypothalamic cells.
Applications for social security benefits related to diabetes in the working age in Italy between 2009 and 2019: a nationwide retrospective study
Case Report: Post-gastrectomy reactive hyperinsulinemic hypoglicaemia: glucose trends before and after canagliflozin treatment
The pathogenesis of post-gastrectomy reactive hyperinsulinaemic hypoglycaemia is not yet fully clarified. Recent studies suggest an up-regulation of the intestinal glucose transporter SGLT-1 aimed to prevent carbohydrate malabsorption. The overexpression of SGLT-1 could therefore represents one of the mechanisms underlying the wide glycemic excursions found in patients after gastrectomy, but studies investigating the use of SGLT-1/SGLT-2 inhibitors in patients with post-gastrectomy reactive hyperinsulinemic hypoglycaemia are very scant in the literature. We report the case of a 37-year-old non diabetic man who frequently presented symptoms of hypoglycaemia in the postprandial period. In 2012, he underwent Roux en-Y gastric bypass (RYGB) and after two years, he started to experience typical symptoms of reactive hyperinsulinaemic hypoglycaemia. We suggested healthy modifications of dietary habits and periodic follow-up visits with a dietitian. After three months, the patient still presented symptoms of reactive hypoglycaemia; we provided him with Flash Glucose Monitoring (FGM) to assess trend of glucose levels in interstitial fluid during the day and we decided to introduce canagliflozin 300 mg/day before the main meal. Hypoglycaemic events previously referred by the patient and clearly recorded by FGM completely disappeared taking canagliflozin. We found a reduction of time spent in hypoglycaemia, an improvement of glycemic variability and an increase of time in target range. It was also noted a reduction of time spent in hyperglicemia with consequent improvement of average glucose values and of glucose main indicator. This is the first report with FGM supporting a role of canagliflozin in the management of post-gastrectomy reactive hyperinsulinaemic hypoglycaemia. Our preliminary results are very limited but in line with those of the literature and showed for the first time a reduction of hypoglycaemic events and an improvement of glycemic variability through a flash glucose monitoring system. Further studies are mandatory to confirm this therapeutic opportunity
Genetic prenatal RET testing and pregnancy management of multiple endocrine neoplasia Type II A (MEN2A): A case report
New understandings of the genetic basis of isolated idiopathic central hypogonadism
Idiopathic hypogonadotropic hypogonadism is a rare disease that is characterized by delayed/absent puberty and/or infertility due to an insufficient stimulation of an otherwise normal pituitary-gonadal axis by gonadotrophin-releasing hormone (GnRH) action. Because reduced or normal luteinizing hormone (LH)/follicle-stimulating hormone (FSH) levels may be observed in the affected patients, the term idiopathic central hypogonadism (ICH) appears to be more appropriate. This disease should be distinguished from central hypogonadism that is combined with other pituitary deficiencies. Isolated ICH has a complex pathogenesis and is fivefold more prevalent in males. ICH frequently appears in a sporadic form, but several familial cases have also been reported. This finding, in conjunction with the description of numerous pathogenetic gene variants and the generation of several knockout models, supports the existence of a strong genetic component. ICH may be associated with several morphogenetic abnormalities, which include osmic defects that, with ICH, constitute the cardinal manifestations of Kallmann syndrome (KS). KS accounts for approximately 40% of the total ICH cases and has been generally considered to be a distinct subgroup. However, the description of several pedigrees, which include relatives who are affected either with isolated osmic defects, KS, or normo-osmic ICH (nICH), justifies the emerging idea that ICH is a complex genetic disease that is characterized by variable expressivity and penetrance. In this context, either multiple gene variants or environmental factors and epigenetic modifications may contribute to the variable disease manifestations. We review the genetic mechanisms that are presently known to be involved in ICH pathogenesis and provide a clinical overview of the 227 cases that have been collected by the collaborating centres of the Italian ICH Network
Natural and synthetic retinoids in prostate cancer
Abstract: Prostate cancer (PCa) is the most common cancer for men in Europe, North America, and some parts of Africa.
Initially, growth of prostate cancer is usually androgen-dependent, but often it becomes androgen-independent after androgen-
deprivation therapy. Managing hormone-refractory prostate carcinoma remains a difficult challenge for clinicians.
Retinoids, vitamin A and its synthetic analogs are one of the most studied class of chemopreventive drugs for PCa. Retinoids
play a key role in several vital functions as vision and development, and also exert anti-proliferative actions. Antiproliferative
effects of retinoids rely on the regulation of many biological processes, including differentiation, cell proliferation,
and apoptosis. Retinoid actions are mediated by two classes of nuclear proteins called retinoic acid (RARa,b and
g and retinoic a,b and g receptors, which are ligand-regulated transcription factors. Effects of both all-trans -retinoic acid
(RA), the natural active derivative of vitamin A, and its synthetic derivatives, on prostate gland or prostate cell lines implicate
retinoids in the regulation of prostate growth and suppression of PCa development. Deficient retinoid availability
and action at the cellular level because of either decreased content or altered metabolism in PCa cells can play a key role
in abnormal cellular differentiation pathways, and the loss of anti-proliferative effects. Here we review the in vitro and in
vivo effects of retinoids in PCa
- …